400-998-5282
专注多肽 服务科研
400-998-5282
专注多肽 服务科研
G280-9 是含有 9 个氨基酸的天然表位肽。G280-9 是在黑素瘤上表达的相关靶蛋白。
G280-9 is a 9 amino acid native epitope peptide. G280-9 is a relevant target expressed on melanoma.
G280-9醋酸盐是一种含有9个氨基酸的天然表位肽，是黑色素瘤表达的相关靶点。它是一种常见的黑色素瘤gp100表位，受MHC相关HLA-A2的限制。
G280-9 acetate is a natural epitope peptide containing 9 amino acids and is a relevant target for melanoma expression. It is a common melanoma gp100 epitope that is restricted by MHC-associated HLA-A2.
Peptide H-YLEPGPVTA-OH is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-YLEPGPVTA-OH include the following: Peptide-Based Active Immunotherapy in Cancer S Schroter, B Minev - Cancer Vaccines, 2008 - ndl.ethernet.edu.ethttp://ndl.ethernet.edu.et/bitstream/123456789/28867/1/Cancer%20vaccines%20%20challenges%20and%20opportunities%20in%20translation.pdf#page=124 Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine OY Borbulevych , TK Baxter, Z Yu - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/8/4812/1745 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues. MR Parkhurst, ML Salgaller, S Southwood - (Baltimore, Md.: 1950 , 1996 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/157/6/2539/29960 Identification of peptides for immunotherapy of cancer. It is still worth the effort MP Velders, JD Nieland , MP Rudolf - Critical Reviewsâ\x84¢in , 1998 - dl.begellhouse.comhttps://www.dl.begellhouse.com/journals/2ff21abf44b19838,4214e868375e8210,1866d6eb25ae7e48.html Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Peripheral Blood Lymphocytes Stimulated in Vitro with Synthetic Peptides ML Salgaller, A Afshar, FM Marincola, L Rivoltini - Cancer research, 1995 - AACRhttps://aacrjournals.org/cancerres/article-abstract/55/21/4972/501669 A Novel Class of Peptides That Induce Apoptosis and Abrogate Tumorigenesisin Vivo M Resnicoff, Z Huang, D Herbert , D Abraham - Biochemical and , 1997 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X97976403 Competition among peptides in melanoma vaccines for binding to MHC molecules LW Thompson, CF Garbee, S Hibbitts - Journal of , 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/11000/competition_among_peptides_in_melanoma_vaccines.2.aspx Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies KA Chianese-Bullock, ST Lewis, NE Sherman - Vaccine, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X09000553 Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein K Nilges, H HoÃ\x8cË\x86hn, H Pilch, C Neukirch - Journal of , 2003 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.77.9.5464-5474.2003 Mass-spectrometric evaluation of HLA-A* 0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100 JCA Skipper, PH Gulden - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990827)82:5%3C669::AID-IJC9%3E3.0.CO;2-%23 Autologous CTL clones derived from PBL recognize a melanoma antigenic peptide encoded by gene Pmel17/gp100-T cell receptor hypervariable region analysis of H Zarour, F Lehmann, C De Smet, JC Renauld - Journal of Investigative , 1995 - infona.plhttps://www.infona.pl/resource/bwmeta1.element.elsevier-afa42e87-170a-3ab5-a66f-414d48be780e Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients GV Yamshchikov, DL Barnd, S Eastham - journal of cancer, 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0215(20010601)92:5%3C703::AID-IJC1250%3E3.0.CO;2-5 Degradation of the immunogenic peptide gp100280-288 by the monocyte-like U937 cell line F Albo, A Cavazza, B Giardina, S Lippa, M Marini - Peptides, 2003 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0196978103000512 Degradation of the tumor antigen epitope gp100280-288 by fibroblast-associated enzymes abolishes specific immunorecognition F Albo, A Cavazza, B Giardina, M Marini - et Biophysica Acta (BBA , 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304416504000170 The binding and presentation of peptide antigens by class I major histocompatibility molecules EL Huczko - 1997 - search.proquest.comhttps://search.proquest.com/openview/6f2bb6d471e685308246ef712dbcb508/1?pq-origsite=gscholar&cbl=18750&diss=y Stability of Multi-Peptide Vaccines in Conditions Enabling Accessibility in Limited Resource Settings E Ashkani, B McKenna, J Bryant, D Silva, N Sherman - 2024 - researchsquare.comhttps://www.researchsquare.com/article/rs-4345166/latest Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans D van Dinther , M Lopez Venegas, H Veninga, K Olesek - Cancers, 2019 - mdpi.comhttps://www.mdpi.com/2072-6694/11/2/183 Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently CL Slingluff Jr , GR Petroni - Journal of Clinical , 2004 - researchgate.nethttps://www.researchgate.net/profile/James-Patterson-13/publication/8183809_Immunologic_and_Clinical_Outcomes_of_Vaccination_With_a_Multiepitope_Melanoma_Peptide_Vaccine_Plus_Low-Dose_Interleukin-2_Administered_Either_Concurrently_or_on_a_Delayed_Schedule/links/578cf9dd08ae5c86c9a64ecf/Immunologic-and-Clinical-Outcomes-of-Vaccination-With-a-Multiepitope-Melanoma-Peptide-Vaccine-Plus-Low-Dose-Interleukin-2-Administered-Either-Concurrently-or-on-a-Delayed-Schedule.pdf Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes CL Slingluff Jr , G Yamshchikov, P Neese - Clinical Cancer , 2001 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/7/10/3012/288802 Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines AL Cox , J Skipper, Y Chen, RA Henderson , TL Darrow - Science, 1994 - science.orghttps://www.science.org/doi/abs/10.1126/science.7513441 Positive and negative modulation of peptidases by pro-inflammatory cytokines A Cavazza, M Marini , GC Spagnoli , LG Roda - Peptides, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0196978108002775
Pass HA, et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23. : https://www.ncbi.nlm.nih.gov/pubmed/9815296
多肽H2N-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-COOH的合成步骤：
1、合成CTC树脂：称取1.0g CTC Resin（如初始取代度约为1.1mmol/g）和1.32mmol Fmoc-Ala-OH于反应器中，加入适量DCM溶解氨基酸（需要注意，此时CTC树脂体积会增大好几倍，避免DCM溶液过少），再加入3.3mmol DIPEA（Mw：129.1,d：0.740g/ml），反应2-3小时后，可不抽滤溶液，直接加入1ml的HPLC级甲醇，封端半小时。依次用DMF洗涤2次，甲醇洗涤1次，DCM洗涤一次，甲醇洗涤一次，DCM洗涤一次，DMF洗涤2次（这里使用甲醇和DCM交替洗涤，是为了更好地去除其他溶质，有利于后续反应）。得到 Fmoc-Ala-CTC Resin。结构图如下：
2、脱Fmoc：加3倍树脂体积的20%Pip/DMF溶液，鼓氮气30分钟，然后2倍树脂体积的DMF 洗涤5次。得到 H2N-Ala-CTC Resin 。（此步骤脱除Fmoc基团，茚三酮检测为蓝色，Pip为哌啶）。结构图如下：
3、缩合：取3.3mmol Fmoc-Thr(tBu)-OH 氨基酸，加入到上述树脂里，加适当DMF溶解氨基酸，再依次加入6.6mmol DIPEA，3.14mmol HBTU。反应30分钟后，取小样洗涤，茚三酮检测为无色。用2倍树脂体积的DMF 洗涤3次树脂。（洗涤树脂，去掉残留溶剂，为下一步反应做准备）。得到Fmoc-Thr(tBu)-Ala-CTC Resin。氨基酸：DIPEA：HBTU：树脂=3：6：2.85：1（摩尔比）。结构图如下：
4、依次循环步骤二、步骤三，依次得到
H2N-Thr(tBu)-Ala-CTC Resin
Fmoc-Val-Thr(tBu)-Ala-CTC Resin
H2N-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Pro-Val-Thr(tBu)-Ala-CTC Resin
H2N-Pro-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
H2N-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
H2N-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
H2N-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
H2N-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
Fmoc-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin
以上中间结构，均可在专肽生物多肽计算器-多肽结构计算器中，一键画出。
最后再经过步骤二得到 H2N-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-CTC Resin，结构如下：
5、切割：6倍树脂体积的切割液（或每1g树脂加8ml左右的切割液），摇床摇晃 2小时，过滤掉树脂，用冰无水乙醚沉淀滤液，并用冰无水乙醚洗涤沉淀物3次，最后将沉淀物放真空干燥釜中，常温干燥24小试，得到粗品H2N-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-COOH。结构图见产品结构图。
切割液选择：1）TFA：H2O=95%：5%、TFA：H2O=97.5%：2.5%
2）TFA：H2O：TIS=95%：2.5%：2.5%
3）三氟乙酸：茴香硫醚：1，2-乙二硫醇：苯酚：水=87.5%：5%：2.5%：2.5%：2.5%
（前两种适合没有容易氧化的氨基酸，例如Trp、Cys、Met。第三种适合几乎所有的序列。）
6、纯化冻干：使用液相色谱纯化，收集目标峰液体，进行冻干，获得蓬松的粉末状固体多肽。不过这时要取小样复测下纯度 是否目标纯度。
7、最后总结：
杭州专肽生物技术有限公司（ALLPEPTIDE https://www.allpeptide.com）主营定制多肽合成业务，提供各类长肽，短肽，环肽，提供各类修饰肽，如：荧光标记修饰（CY3、CY5、CY5.5、CY7、FAM、FITC、Rhodamine B、TAMRA等），功能基团修饰肽（叠氮、炔基、DBCO、DOTA、NOTA等），同位素标记肽（N15、C13），订书肽（Stapled Peptide）,脂肪酸修饰肽（Pal、Myr、Ste），磷酸化修饰肽（P-Ser、P-Thr、P-Tyr），环肽（酰胺键环肽、一对或者多对二硫键环），生物素标记肽，PEG修饰肽，甲基化修饰肽
以上所有内容，为专肽生物原创内容，请勿发布到其他网站上。
